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INTRODUCTION
Numerous studies have demonstrated that T-cell deple-
tion of donor bone marrow at the time of marrow transplan-
tation reduces the incidence and severity of graft-versus-host
disease (GVHD) [1-3]. T-cell depletion also appears to be
associated with a reduced incidence of other transplanta-
tion-related complications, such as interstitial pneumonitis
and veno-occlusive disease (VOD), which contribute to
transplantation-related morbidity and mortality [3,4].
Although T-cell depletion may be associated with a reduced
risk of complications, studies have demonstrated an
increased risk of relapse in diseases such as chronic myel-
ogenous leukemia (CML) by abrogation of the graft-versus-
leukemia (GVL) effect [5,6].
Several approaches to address the increased relapse
rate following T-cell–depleted (TCD) bone marrow trans-
plantation (BMT) have been investigated, such as the
intensification of the ablative regimen. The rationale for
this approach after TCD BMT stems from the experience
in T-cell–replete transplantation, in which efforts to
intensify the ablative regimen with the use of additional
chemotherapy agents or the intensification of standard
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ABSTRACT
Prior studies of non–T-cell–depleted (TCD) transplantation have demonstrated a reduction in relapse in patients
receiving escalated doses of TBI; however, overall survival in these studies was not significantly improved due to
increased treatment-related toxicity seen at the higher doses of irradiation. Toxicity was in part related to an
increased incidence of GVHD. Because T-cell depletion of donor bone marrow reduces the incidence of GVHD
and other treatment-related complications after allogeneic bone marrow transplantation, it was postulated that TBI
dose may be safely escalated in this setting and may decrease the risk of relapse following TCD BMT. Herein, we
report the results of a trial assessing the safety and impact of escalated doses of TBI after TCD BMT. Two hundred
adults with hematologic malignancies were treated in consecutive cohorts defined by increasing doses of TBI (1400,
1480, and 1560 cGy) in combination with cyclophosphamide. In vitro T-cell depletion using anti-CD6 monoclonal
antibody was used for GVHD prophylaxis. The incidence of grade II or greater acute GVHD in patients receiving
1560 cGy (36%) was significantly higher than in patients receiving 1400 cGy (18%) (P = .04) or 1480 cGy (13%) (P =
.01). Two-year treatment-related mortality was significantly higher in patients who received 1560 cGy of TBI (33%)
than in those who received 1400 cGy (20%) (P = .04) or 1480 cGy (19%) (P = .05). The increased dose of TBI did
not reduce the rates of relapse, with the estimated 2-year risk of relapse being 24% (1400 cGy), 24% (1480 cGy),
and 31% (1560 cGy) for the 3 cohorts of patients. Overall survival at 2 years was inferior for patients receiving 1560 cGy
of TBI (36%) compared with those who received 1400 cGy (55%) or 1480 cGy (58%) (P = .01). We conclude that
dose escalation of TBI is associated with increased GVHD and inferior survival following TCD BMT. Future efforts
to reduce the risk of relapse after TCD BMT should focus on immunologic methods to induce the graft-versus-
leukemia effect after BMT rather than intensification of the ablative regimen by escalation of irradiation dose.
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agents has led to a reduction in relapse after BMT. Previ-
ous randomized trials in patients with CML or acute
leukemia have demonstrated that escalation of the dose of
total body irradiation (TBI) from 1200 cGy to 1575 cGy
reduces the risk of relapse in patients receiving unmanipu-
lated marrow [7,8]. Unfortunately, increased toxicity was
noted at the higher TBI dose, and no benefit of long-term
disease-free survival was noted. Complications of increas-
ing the dose of TBI included an increased incidence of
pulmonary complications and GVHD. The contributions
to the reduction in relapse rate of the increased dose of
TBI and resulting increased incidence of GVHD noted in
the patients receiving the higher dose of irradiation are
not known.
The effects of increasing the intensity of TBI have not
been directly studied in patients receiving TCD trans-
plants. Increased doses of TBI may be associated with
decreasing the incidence of relapse after BMT either by
direct cytotoxic effect on the malignant clone or by
decreasing the incidence of mixed chimerism after BMT,
which has been associated with an increased risk of relapse.
It has been hypothesized that it may be safer to escalate
TBI in patients receiving TCD transplants because the
incidence of GVHD and pulmonary complications is often
lower after TCD BMT than after T-cell–replete BMT [4].
In this report, we have assessed the safety of intensifying
the ablative regimen by escalating the dose of TBI prior to
TCD transplantation. Three doses of TBI were explored:
1400 cGy, 1480 cGy, and 1560 cGy. We have had extensive
experience with a TBI dose of 1400 cGy with minimal
treatment-related toxicity. Given the steep dose-toxicity
curve noted at escalated doses of TBI, we have escalated the
TBI dose over a small range, with the highest TBI dose
(1560 cGy) in this trial being less than the dose (1575 cGy)
that was associated with significant toxicity in prior non-
TCD BMT trials [7,8]. Patients were followed for relapse,
GVHD, and overall survival.
MATERIAL AND METHODS
The patients included in this analysis comprise 200 adults
who underwent allogeneic BMT from HLA-identical sib-
ling donors at our institution between January 1, 1990, and
February 1, 1998. Patients were initially treated on a proto-
col in which they received 1400 cGY of TBI. A subsequent
protocol TBI dose escalation study examining 1480 cGy and
1560 cGy was performed. The distribution of diagnoses are
listed in Table 1. Patients classiﬁed as having early-stage dis-
ease included patients with acute myelogenous leukemia
(AML), patients with and acute lymphoblastic leukemia
(ALL) in first complete remission, and patients with first
stable phase CML. Advanced-stage patients were deﬁned as
patients with AML, ALL in second or subsequent remission
or untreated first relapse, CML in accelerated or blast
crisis ,  non-Hodgkin’s lymphoma (NHL), multiple
myeloma, and patients with myelodysplastic syndrome.
The median follow-up for the 68 patients last known to be
alive was 56 months (range, 5-112 months). Treatment
protocols were approved by the institutional review board
and the Dana-Farber Cancer Institute. Written informed
consent was obtained in all cases.
Treatment Protocol
All patients received cyclophosphamide 60 mg/kg on
2 successive days followed by TBI as ablation therapy. Three
dose levels of TBI were examined: 1400 cGy, 1480 cGy, and
1560 cGy. All patients treated between 1990 and 1993
received 1400 cGy. These patients served as a control popu-
lation to the patients treated at higher doses of TBI.
Beginning in 1993, in an attempt to reduce the risk of
relapse, consecutive cohorts of patients were treated with
1480 cGy and 1560 cGy of TBI. Because patients with early
and advanced disease are expected to have different rates of
treatment-related complications, the dose escalation was con-
ducted independently in the 2 groups. The expected treat-
ment-related mortality (TRM) rates based on historical data
were 5% for early-stage patients and 20% for advanced-stage
patients. Initially, 10 early-stage patients and 10 advanced-
stage patients were treated at 1480 cGy. At the 3-month
follow-up after BMT, treatment-related toxicity was assessed
in each group. If toxicity was less than or equal to an expected
TRM, patient groups were escalated to the next TBI dose
level; if the frequency of events noted required further patient
accrual to better assess treatment-related toxicity, an addi-
tional 10 patients were accrued to the current dose level.
Accrual to the study was much more rapid for advanced-stage
patients, and accrual was completed to both the 1480 cGy
and 1560 cGy dose levels for advanced-stage patients without
a higher-than-expected increase in TRM in the ﬁrst 3 months
after transplantation. Increased toxicity was noted in the ﬁrst
cohort of early-stage patients enrolled at 1560 cGy, and
accrual of the early-stage patients to this dose level was
terminated early. Accrual of advanced-stage patients to the
1560 cGy dose level was completed. Given the increased toxi-
city noted in early-stage patients treated at 1560 cGy, subse-
quent patients were then treated with 1480 cGy.
The maximum TBI dose explored, 1560 cGy, was cho-
sen to be less than TBI doses reported in the literature to
be associated with increased toxicity [7,8]. In an effort to
reduce toxicity, the maximum fraction dose was 200 cGy.
One hundred patients received 1400 cGy administered as
7 equal 200-cGy fractions. Sixty-four patients received
1480 cGy administered in 8 equal 185-cGy fractions, and
36 patients received 1560 cGy in 8 equal 195-cGy frac-
tions. Fractions were administered twice daily with 5.5 to
6 hours between fractions for 4 days. All patients were
treated in a dedicated facility and doses administered at
10 cGy/min. TBI was administered with dual-headed 4-mega-
voltage linear accelerators providing radiation from front
and back simultaneously [9,10]. Front and back lung
shielding (3/16 of an inch of lead) was used on all patients
to provide uniform dosimetry.
Bone marrow was harvested on the last day of TBI
administration. T-cell depletion was performed using anti-
CD6 monoclonal antibody and complement lysis, as previ-
ously described [11]. Marrow was infused into the patient
via an indwelling catheter the same day that it was har-
vested. The day of marrow infusion was designated day 0.
No other prophylactic immune suppressive therapy was
given. Since January 1994, all patients received granulocyte
colony-stimulating factor (G-CSF) at 5 µg/kg per day begin-
ning at day 1, continuing until the absolute neutrophil count
(ANC) exceeded 1 × 109 cells/L.
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All patients were treated in high-efficiency particulate
air (HEPA)-ﬁltered rooms using standard reverse isolation
procedures. Oral prophylactic antibiotics were administered
to all patients. Broad-spectrum intravenous antibiotics were
administered and oral antibiotics were discontinued at the
time of development of fever. All blood components were
irradiated to prevent transfusion-related GVHD.
Statistical Methods
Descriptive statistics are reported as proportions, medi-
ans, and means. The Fisher exact test was used to compare
proportions [12]. Survival, time to treatment failure, time to
relapse, and time to death in remission curves were con-
structed using the Kaplan-Meier product-limit method [13].
All time-to-event endpoints were measured from the date of
marrow infusion. Overall survival estimates use death as an
event and censor patients alive at last follow-up. Disease-
free survival takes relapse and death in remission as uncen-
sored endpoints. Time to relapse uses relapse as an event
and censors both patients who are alive and well and those
who die in remission; time to death in remission identiﬁes
only death in remission as an event and censors patients who
remain alive as well as those who have died following
relapse. Time to relapse and time to death in remission
reﬂect competing risks; cumulative incidence functions were
estimated and P values reported, reﬂecting this competing
risks structure. Patients dying after posttransplantation
relapse from any cause are defined as dying from relapse-
related complications. Deaths in patients who did not
relapse are deﬁned as TRM. The log-rank test was used to
compare the various subgroups with respect to these time-
to-event endpoints. The Fisher exact test and Wilcoxon
rank sum test were used to identify possible predictors of
grades 2, 3, or 4 acute GVHD. P values without annotation
compare the 3 dose levels of TBI; comparisons of the 2 lower
dose levels or of the 2 lower dose levels versus 1560 cGy are
reported with nominal P values, without adjustment for
multiple comparisons. Cox proportional hazards multiple
regression was used to identify risk factors for relapse and
death, using time-to-event endpoints as deﬁned above.
RESULTS
Patient Population
Two hundred consecutive patients who underwent allo-
geneic BMT from HLA-identical siblings were analyzed
(Table 1). The majority of patients treated (125 patients) had
leukemia. Fifty-ﬁve patients had CML, 48 patients had AML,
and 22 patients had ALL. Fifteen patients had myelodysplas-
tic syndrome, 24 had NHL, 1 had Hodgkin’s disease, 1 had
myeloproliferative disorder (agnogenic myeloid metaplasia
with myeloﬁbrosis), and 34 had multiple myeloma. Eighty-
two patients were deﬁned as having early-stage disease, and
118 patients were deﬁned as having advanced-stage disease.
One hundred patients received 1400 cGy of TBI, 64 patients
received 1480 cGy, and 36 patients received 1560 cGy. The
median age of all patients was 41 years (range, 18-65 years).
The median age of the donors was 39 years (range, 16-
71 years). There were 106 men and 94 women. The median
number of days in the hospital was also similar between
patients receiving different dose levels of TBI. The median
number of nucleated cells infused was 5.50 × 107 cells/kg.
There was no signiﬁcant difference between the TBI dose-
level cohorts in the number of cells infused.
Table 1. Patient Characteristics*
1400 cGy 1480 cGy 1560 cGy Overall
No. of Patients 100 64 36 200
Men 47 36 23 106
Women 53 28 13 94
Patient age, y (range) 39 (18-59) 43 (22-65) 42 (21-60) 41 (18-65)
Donor age, y (range) 38 (16-67) 42 (16-66) 41 (23-71) 49 (16-71)
Patient/donor sex
M/M 28 18 13 59
M/F 19 18 10 47
F/M 32 11 8 51
F/F 21 17 5 43
Disease
Early stage, % 41 50 25 41
Stable phase CML 25 17 4 46
AML CR 1 12 14 4 30
ALL CR 1 4 1 1 6
Advanced stage, % 59 50 75 59
MDS 4 4 7 15
AML 10 4 4 18
ALL 10 4 2 16
MM 20 6 8 34
Advanced CML 6 3 0 9
NHL 9 9 6 24
Hodgkin’s disease 0 1 0 1
Other 0 1 0 1
*CR indicates complete remission; MDS, myelodysplastic syndrome; MM, multiple myeloma.
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Engraftment
Of the 200 patients, 199 patients underwent successful
engraftment after infusion of TCD marrow. One patient with
CML treated with 1480 cGy developed primary graft failure.
Six patients developed evidence of late graft failure. Three of
these patients had received 1400 cGy, 2 patients received
1480 cGy, and 1 patient received 1560 cGy, representing a
3% incidence of late graft failure at each dose level. Prior to
the use of G-CSF, the median time to reach an ANC greater
than 500 cells/L was 20 days (range, 12-43 days). After the
use of G-CSF, the median time to reach an ANC greater than
500 cells/L was 12 days (range, 7-50 days).
Graft-Versus-Host Disease
Of the 200 patients who underwent transplantation, 20%
developed evidence of grades II to IV acute GVHD (Table 2).
Thirty-three patients (17%) developed evidence of grade II
acute GVHD, and 6 patients (3%) developed evidence of
grade III or IV acute GVHD. The dose of TBI signiﬁcantly
inﬂuenced the incidence of acute GVHD (P = .02). There
was an increased incidence of grade II or greater acute
GVHD in patients receiving 1560 cGy TBI compared with
those receiving either 1400 cGy (P = .04) or 1480 cGy (P =
.01). The incidence of grade II or greater acute GVHD at
1560 cGy was 36% in contrast to 18% at 1400 cGy and 13%
at 1480 cGy. There was no signiﬁcant difference in the inci-
dence of grade II or greater GVHD between the 1480 cGy
and 1400 cGy groups (P = .39).
Relapse
Increasing the dose of TBI did not result in a decrease
in relapse rate, despite the increased incidence of GVHD
noted at the higher dose of TBI (Figure 1). The 2-year
estimated risk of relapse was 24% for patients receiving
1400 cGy, 24% at 1480 cGy, and 31% at 1560 cGy (P =
.64, log-rank test). When analyzed by stage of disease at
the time of transplantation, no difference in relapse rate
was noted between TBI doses in patients with early versus
advanced disease.
Treatment-Related Complications
TRM was increased at the highest dose of TBI (Figure 2).
The 2-year TRM was 20% for patients treated with 1400 cGy,
19% for 1480 cGy, and 33% for 1560 cGy (P = .08). TRM
among patients treated with 1560 cGy was signiﬁcantly higher
than that among patients treated at 1400 cGy (P = .04) or at
1480 cGy (P = .05). Causes of overall mortality are outlined in
Figure 3. The majority of deaths were related to relapse. Non-
infectious pneumonia and infectious complications were the
most frequent non–relapse-related causes of death. Epstein-
Barr virus–related lymphoproliferative disease occurred in
2 patients (1%) of all those treated. Two deaths were directly
related to GVHD.
Survival
With no difference in risk of relapse between TBI doses
and increased TRM with the higher TBI dose, overall survival
was inferior for patients receiving high-dose TBI, 1560 cGY,
compared with those receiving the lower TBI doses of
1400 cGy and 1480 cGy (P = .01, log-rank test) (Figure 4).
The 2-year overall survival rate was 55% for patients receiv-
ing 1400 cGy, 58% for those receiving 1480 cGy, and 36%
for those receiving 1560 cGy (P = .01). The difference in
survival is accounted for by the inferior results obtained in
early-stage patients treated at 1560 cGy compared to those
treated with lower doses of TBI (P = .05). The median
follow-up for patients remaining in remission after receiving
Table 2. Incidence of GVHD at Deﬁned Doses of TBI
Acute 1400 cGy, 1480 cGy, 1560 cGy, Total,
GVHD n (%) n (%) n (%) n (%)
0 52 (52) 37 (58) 14 (39) 103 (52)
I 30 (30) 19 (30) 9 (25) 58 (29)
II 14 (14) 7 (11) 12 (33) 33 (17)
III-IV 4 (4) 1 (2) 1 (3) 6 (3)
Figure 1. Risk of relapse following T-cell–depleted BMT. The cumula-
tive risk of relapse after transplantation is compared for 3 doses of TBI.
The 2-year estimated risk of relapse was similar between groups (P = .64).
Figure 2. Treatment-related mortality following T-cell–depleted
BMT. The cumulative risk of treatment-related mortality is compared
for 3 doses of TBI.
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1400 cGy was 83 months, for 1480 cGy was 29 months, and
for 1560 cGy was 47 months.
Step-wise Cox proportional hazards regression models
were constructed to identify clinical factors associated with
differences in overall survival. Receiving 1560 cGy resulted
in an increased hazard ratio of 1.7 (90% conﬁdence interval
[CI], 1.2-2.5) compared with the lower doses of TBI (P =
.02). An increased hazard ratio of 1.7 (90% CI, 1.2-2.4) was
also noted in patients with advanced-stage disease compared
with patients with early-stage disease (P = .002).
DISCUSSION
TCD allogeneic BMT is associated with a lower inci-
dence of GVHD and transplantation-related complications.
Despite this reduction, several large studies have demon-
strated improved disease-free survival in patients receiving
T-cell–replete BMT due to the increased relapse rate
observed in some diseases following TCD BMT [5,6]. Our
ﬁndings indicate that increasing the intensity of the ablative
regimen by escalating the dose of TBI to 1560 cGy does not
significantly reduce the risk of relapse after CD6 TCD
BMT but does increase the risk of GVHD and TRM. The
risk of relapse was not changed in patients receiving 1560 cGy
of TBI despite the increase in GVHD seen at that dose.
A previous report examining TBI dose in patients with
AML in ﬁrst complete remission undergoing BMT demon-
strated a reduced risk of relapse in patients receiving 1575 cGy
compared to that in patients receiving 1200 cGy [7]. In a
recent update of this study with over 7 years of follow-up,
patients receiving the high dose of radiation continue to
demonstrate significantly lower relapse rates compared to
patients receiving TBI at the lower dose [14]. Despite the
difference in relapse rate, there remains no difference in
event-free survival or overall survival with the extended fol-
low-up. The increased nonrelapse mortality seen in patients
receiving high-dose TBI was noted in the first 6 months
after BMT. The authors concluded that the increased TBI
dose is associated with more effective elimination of the
malignant disease. A similar result was obtained in patients
with CML randomized to receive 1575 cGy or 1200 cGy of
TBI [8]. A recent report of 16 patients suggested that escala-
tion of TBI doses to 1440 cGy and 1530 cGy in conjunction
with VP-16 (etoposide) did not increase treatment-related
toxicity. However, this report only includes a small number
of subjects with a short follow-up [15].
There are several possible explanations why a decrease
in relapse rate was not observed in our study compared with
previous reports. It is possible that the lowest dose of TBI in
this study, 1400 cGy, was above a threshold above which
further escalations in TBI dose may not lead to more effec-
tive eradication of the malignancy. Our study also contains a
heterogeneous group of patients, and it is possible that ben-
eficial effects of higher TBI doses will not be observed in
some speciﬁc diseases. However, in the current study, a mul-
tivariate analysis does not identify speciﬁc disease states that
beneﬁt from escalated TBI doses. Finally, GVHD prophy-
laxis with T-cell depletion may also impact the relapse rate
in this study. The increased doses of TBI may not be able to
overcome the abrogation of the GVL effect created by T-cell
depletion despite the increased incidence of GVHD, in sup-
port of the notion that T-cell depletion may increase relapse
rate by mechanisms independent of its direct effect on low-
ering the incidence of GVHD.
In our study there does appear to be a relationship
between TBI dose and GVHD, conﬁrming human and ani-
mal studies. Experimental murine transplantation models
suggest that high-dose radiation increases damage to the
gastrointestinal tract and increases the sensitivity of macro-
phages to endotoxin [16]. Increased damage to the gastroin-
testinal tract leads to increased release of lipopolysaccharide
(LPS), which is associated with increased levels of circulat-
ing tumor necrosis factor α and interleukin (IL)-1β. Blocking
cytokine pathways in experimental transplantation models
has reduced GVHD; however, trials of agents that block
these cytokine pathways in adults undergoing BMT have
not led to a reduction in GVHD [16].
Our studies suggest that strategies to reduce relapse fol-
lowing TCD BMT aimed at intensifying the ablative regi-
men should not be pursued. Because increasing the intensity
of the ablative regimen may not be a successful strategy,
Figure 3. Causes of treatment-related mortality after T-cell–depleted
BMT. EBV indicates Epstein-Barr virus; LPD, lymphoproliferative
disorder.
Figure 4. Overall survival. The overall survival of patients after trans-
plantation is contrasted for 3 doses of TBI.
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efforts should now focus on methods to induce immuno-
logic strategies to reduce relapse. In diseases that are sensi-
tive to a GVL effect, attention should focus on methods to
enhance the GVL effect as a means of reducing relapse after
transplantation and improving overall survival. Nonmye-
loablative transplantation strategies that reduce the intensity
of the ablative regimens are now being explored [17-19].
The success of “mini” transplantation is based on the induc-
tion of a GVL effect after transplantation during the taper
of immune suppressive medications or by donor lymphocyte
infusion. Other methods of immune modulation to enhance
the GVL effect after BMT may include the use of either
cytokines, such as IL-2 or IL-12, or the prophylactic infu-
sion of donor lymphocytes.
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